11. Myasthenia gravis Clinical trials / Disease details

Clinical trials : 315 / Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04101578 (ClinicalTrials.gov)	February 8, 2017	16/9/2019	Clinical Prognosis and Progression of Myasthenia Gravis Patients	Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients	Myasthenia Gravis	Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)	Da, Yuwei, M.D.	NULL	Recruiting	15 Years	N/A	All	2000		China
2	JPRN-UMIN000015019	2014/09/02	02/09/2014	Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG		Myasthenia gravis	Tacrolimus and IVIG	Kansai medical university	NULL	Recruiting	Not applicable	Not applicable	Male and Female	20	Not applicable	Japan
3	NCT01179893 (ClinicalTrials.gov)	March 2007	9/8/2010	Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis	A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis	Myasthenia Gravid	Biological: IVIG;Procedure: PLEX	University Health Network, Toronto	Grifols Therapeutics Inc.	Completed	18 Years	N/A	Both	87	Phase 4	Canada
4	NCT00306033 (ClinicalTrials.gov)	March 2004	21/3/2006	Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis	IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial	Myasthenia Gravis	Drug: Intravenous ImmuneGlobulin	University Health Network, Toronto	NULL	Completed	18 Years	N/A	Both	50	Phase 3	Canada